MedTrace Logo

Zotarolimus and Everolimus-Eluting Stents ProsPectively Compared in Real World

NCT00768846 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2600

Last updated 2008-10-15

No results posted yet for this study

Summary

The zotarolimus-eluting Endeavor Resolute stent is not inferior to the everolimus- eluting Xience V stent platform regarding a composite of cardiac death, myocardial infarction or target lesion revascularisation in a real-world population.

Conditions

Interventions

DEVICE

Endeavor Resolute Stent

Zotarolimus-eluting Endeavor Resolute Stent

DEVICE

Xience V Stent

Everolimus-eluting Xience V Stent

Sponsors & Collaborators

  • Deutsches Herzzentrum Muenchen

    lead OTHER

Principal Investigators

  • Adnan Kastrati, MD · Deutsches Herzzentrum Munich

  • Julinda Mehilli, MD · Deutsches Herzzentrum Munich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-05-31
Completion
2011-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00768846 on ClinicalTrials.gov